CA2705486C - Lung cancer markers and uses thereof - Google Patents

Lung cancer markers and uses thereof Download PDF

Info

Publication number
CA2705486C
CA2705486C CA2705486A CA2705486A CA2705486C CA 2705486 C CA2705486 C CA 2705486C CA 2705486 A CA2705486 A CA 2705486A CA 2705486 A CA2705486 A CA 2705486A CA 2705486 C CA2705486 C CA 2705486C
Authority
CA
Canada
Prior art keywords
lcm
protein
lung cancer
proteins
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2705486A
Other languages
English (en)
French (fr)
Other versions
CA2705486A1 (en
Inventor
Charles Birse
Steve Ruben
Marcia Lewis
Mehdi Mesri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celera Corp
Original Assignee
Celera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celera Corp filed Critical Celera Corp
Publication of CA2705486A1 publication Critical patent/CA2705486A1/en
Application granted granted Critical
Publication of CA2705486C publication Critical patent/CA2705486C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8114—Kunitz type inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2705486A 2007-11-19 2008-11-19 Lung cancer markers and uses thereof Active CA2705486C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US376707P 2007-11-19 2007-11-19
US61/003,767 2007-11-19
PCT/US2008/084077 WO2009067546A2 (en) 2007-11-19 2008-11-19 Lung cancer markers and uses thereof

Publications (2)

Publication Number Publication Date
CA2705486A1 CA2705486A1 (en) 2009-05-28
CA2705486C true CA2705486C (en) 2019-04-02

Family

ID=40668079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705486A Active CA2705486C (en) 2007-11-19 2008-11-19 Lung cancer markers and uses thereof

Country Status (5)

Country Link
US (5) US7892760B2 (https=)
EP (3) EP3115469B1 (https=)
JP (4) JP5580205B2 (https=)
CA (1) CA2705486C (https=)
WO (1) WO2009067546A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007006671D1 (de) * 2006-08-01 2010-07-01 Roche Diagnostics Gmbh Verwendung von nnmt als marker für lungenkrebs
US7892760B2 (en) * 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
KR101112113B1 (ko) * 2009-06-18 2012-02-22 인하대학교 산학협력단 암 치료에 대한 타겟으로서의 분비 과립 및 과립형성 인자
EP2470897A4 (en) * 2009-08-28 2013-05-29 Asuragen Inc MICRO-RNA BIOMARKERS OF PULMONARY DISEASE
JP2013505730A (ja) * 2009-10-01 2013-02-21 チップディーエックス エルエルシー 患者を分類するためのシステムおよび方法
WO2011085163A2 (en) * 2010-01-08 2011-07-14 The Regents Of The University Of California Protein markers for lung cancer detection and methods of using thereof
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
CN106706914B (zh) 2010-09-09 2018-10-19 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及单克隆抗体
WO2012054732A2 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
KR101292163B1 (ko) 2010-11-23 2013-08-12 한양대학교 산학협력단 Ｋｒｔ１９ 항체를 포함하는 항암용 조성물
EP2742950B1 (en) * 2011-08-09 2017-03-08 Korea Atomic Energy Research Institute Pharmaceutical composition containing fibulin-3 protein as an active ingredient for inhibiting the growth of cancer stem cells
CA2799163C (en) 2011-12-18 2025-01-07 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US11913957B2 (en) 2011-12-21 2024-02-27 Biodesix, Inc. Compositions, methods and kits for diagnosis of lung cancer
US9201044B2 (en) 2011-12-21 2015-12-01 Integrated Diagnostics, Inc. Compositions, methods and kits for diagnosis of lung cancer
US9304137B2 (en) * 2011-12-21 2016-04-05 Integrated Diagnostics, Inc. Compositions, methods and kits for diagnosis of lung cancer
EP3725892A1 (en) * 2012-03-27 2020-10-21 F. Hoffmann-La Roche AG Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2013154998A1 (en) * 2012-04-09 2013-10-17 Duke University Serum biomarkers and pulmonary nodule size for the early detection of lung cancer
WO2013190090A1 (en) * 2012-06-21 2013-12-27 Philip Morris Products S.A. Gene signatures for classifying and grading lung cancer
JP6030367B2 (ja) * 2012-07-24 2016-11-24 日本光電工業株式会社 細胞解析方法および細胞解析装置
CN102759620B (zh) * 2012-07-27 2015-05-20 复旦大学附属中山医院 用于诊断非小细胞肺癌的试剂盒
US10288626B2 (en) * 2012-09-14 2019-05-14 University Of Kentucky Research Foundation Secreted tumor-associated cytochrome as a blood-based biomarker for cancer
CN102942630A (zh) * 2012-10-17 2013-02-27 杭州德同生物技术有限公司 抗骨桥蛋白抗体
EP2923203B1 (en) * 2012-11-20 2018-10-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Assay to measure midkine or pleiotrophin level for diagnosing a growth
US20140271453A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
US10365281B2 (en) 2013-12-09 2019-07-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
WO2015144860A1 (en) * 2014-03-26 2015-10-01 Goran Landberg Agents inhibiting granulin for treatment of cancer
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
GB201419634D0 (en) * 2014-11-04 2014-12-17 Randox Lab Ltd Lung cancer sub-typing method
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
JP7023841B2 (ja) * 2015-10-23 2022-02-22 エフ．ホフマン－ラ ロシュ アーゲー マーカー分子に基づいて個体を化学療法により処置すべきであると同定する方法および関連する使用
US20170168055A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. SRM/MRM Assays
EP3427051B1 (en) * 2016-03-08 2021-06-16 Magarray, Inc. Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer
CN106519007B (zh) * 2016-12-12 2019-07-02 王家祥 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
KR102080887B1 (ko) 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
WO2019115480A1 (en) * 2017-12-12 2019-06-20 Protagen Ag Melanoma checkpoint inhibitor detection and treatment
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
AU2020233286B2 (en) 2019-03-01 2022-10-20 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
PH12021553167A1 (en) * 2019-06-19 2022-08-15 Celularity Inc Exosomes for disease treatment
AU2020364234A1 (en) * 2019-10-11 2022-04-07 Bioventures, Llc Use of simultaneous marker detection for assessing difuse glioma and responsiveness to treatment
CN113125762A (zh) * 2019-12-31 2021-07-16 瑞博奥(广州)生物科技股份有限公司 一种检测女性恶性肿瘤标志物的检测芯片及其制备方法和应用
CN113125723A (zh) * 2019-12-31 2021-07-16 瑞博奥(广州)生物科技股份有限公司 一种检测男性恶性肿瘤标志物的检测芯片及其制备方法和应用
CA3165068A1 (en) * 2020-01-30 2021-08-05 John E. Blume Lung biomarkers and methods of use thereof
KR20210103212A (ko) * 2020-02-13 2021-08-23 (주) 프로탄바이오 폐암 진단용 다중 바이오마커 및 이의 용도
JP7534426B2 (ja) * 2020-09-09 2024-08-14 株式会社日立ハイテク 代謝物パネルによるがん検査法
EP4285118A1 (en) * 2021-01-28 2023-12-06 3M Innovative Properties Company System and methods for detecting an analyte and transmitting test assay results
CN112946273A (zh) * 2021-02-03 2021-06-11 云南省肿瘤医院(昆明医科大学第三附属医院) 一种新的肺癌转移标志物
WO2022192528A1 (en) * 2021-03-10 2022-09-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Gal3bp polypeptide compositions and methods for treatment of cancer and determining treatment responsiveness
US12334190B2 (en) 2021-03-31 2025-06-17 PrognomIQ, Inc. Multi-omic assessment using proteins and nucleic acids
KR102560020B1 (ko) * 2021-04-29 2023-07-26 연세대학교 산학협력단 암의 진단용 조성물
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
US12007397B2 (en) 2021-09-13 2024-06-11 PrognomIQ, Inc. Enhanced detection and quantitation of biomolecules
CN116482365B (zh) * 2023-03-14 2023-10-20 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用
EP4692801A1 (en) * 2024-08-07 2026-02-11 Siemens Healthineers AG Multi-analyte blood tests tailored to seek, assess, and subtype pulmonary nodules

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
EP0440663A1 (de) 1988-08-08 1991-08-14 IFFIU, Michael A. Klappbares sesselrad mit stromlinienförmiger, in drei geteilter und faltbarer verkleidung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
EP0513209A4 (en) 1990-01-26 1993-08-25 Us Commerce A method for quantitatively measuring collagenase
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
ATE185424T1 (de) 1991-07-29 1999-10-15 Serex Inc Differentielle bindungsaffinitäten und darauf beruhende dissoziationstestverfahren
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
EP1362913B1 (en) 1992-10-30 2006-01-25 The General Hospital Corporation Interaction trap system for isolating proteins
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5508463A (en) 1994-03-17 1996-04-16 Trustees Of The University Of Pennsylvania α-aminophosphonates
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JPH0987299A (ja) * 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk Ｍｍｐ−２活性化因子に特異的なモノクローナル抗体
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
WO1997023782A1 (en) 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6811995B1 (en) 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE19736691A1 (de) 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
ATE400813T1 (de) 1999-09-10 2008-07-15 Takashi Muramatsu Tumormarker für frühes krebsstadium
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
CA2416732C (en) 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
JP4406206B2 (ja) * 2001-04-24 2010-01-27 バイエル コーポレーション ヒトｔｉｍｐ−１抗体
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003001983A2 (en) 2001-06-28 2003-01-09 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating a disease mediated by decreased mmp-2 function
WO2003048734A2 (en) 2001-12-03 2003-06-12 Oncomedx, Inc. Detection of matrix metalloproteinase rna in plasma and serum
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20050272061A1 (en) * 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
CA2588057A1 (en) 2004-10-12 2006-04-20 John Wayne Cancer Institute Treatment of cancer and compositions
US20060235034A1 (en) 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US20060160762A1 (en) 2004-12-13 2006-07-20 Children's Medical Center Corporation Methods for the treatment, diagnosis, and prognosis of cancer
WO2006074367A2 (en) 2005-01-05 2006-07-13 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
WO2006080597A1 (en) * 2005-01-31 2006-08-03 Digital Genomics Inc. Markers for the diagnosis of lung cancer
EP1871911A2 (en) * 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
ATE502048T1 (de) 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
EP1957985A4 (en) * 2005-07-21 2010-01-27 Univ Wayne State INCOMACY WITH ASBEST, PLEURAMESOTHELIOM AND OSTEOPONTIN SERUM CONCENTRATIONS
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP1969363B1 (en) 2005-12-22 2016-11-30 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
BRPI0709425A2 (pt) * 2006-03-29 2011-07-12 Genentech, Inc. uso de um antagonista do vegf e método in vitro para diagnosticar um tumor resistente
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
WO2009013075A2 (en) 2007-06-19 2009-01-29 Dublin City University Markers for invasion in breast and lung carcinoma
US20090004105A1 (en) 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US7892760B2 (en) * 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
WO2009079581A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer

Also Published As

Publication number Publication date
US20090176228A1 (en) 2009-07-09
JP2015143716A (ja) 2015-08-06
JP5580205B2 (ja) 2014-08-27
EP3115469B1 (en) 2020-04-29
US8808997B2 (en) 2014-08-19
JP2017181525A (ja) 2017-10-05
JP2011527414A (ja) 2011-10-27
EP2728017A1 (en) 2014-05-07
CA2705486A1 (en) 2009-05-28
US20170153238A1 (en) 2017-06-01
EP2227556A2 (en) 2010-09-15
WO2009067546A2 (en) 2009-05-28
EP2728017B1 (en) 2016-08-24
US10338075B2 (en) 2019-07-02
JP5812545B2 (ja) 2015-11-17
EP2227556B1 (en) 2014-08-27
JP2014089217A (ja) 2014-05-15
US7892760B2 (en) 2011-02-22
US20120076725A1 (en) 2012-03-29
US20200064347A1 (en) 2020-02-27
US20150037820A1 (en) 2015-02-05
WO2009067546A3 (en) 2009-12-17
US11105806B2 (en) 2021-08-31
EP3115469A1 (en) 2017-01-11
EP2227556A4 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
US11105806B2 (en) Lung cancer markers and uses thereof
US20210292407A1 (en) Cancer targets and uses thereof
US7473531B1 (en) Pancreatic cancer targets and uses thereof
US7842466B1 (en) Colon disease targets and uses thereof
US11802164B2 (en) Methods and compositions for diagnosing and treating diseases
US20110219464A1 (en) Lung disease targets and uses thereof
US20090196873A1 (en) Methods and compositions for treating diseases targeting CDCP1
US20090035299A1 (en) Methods and compositions for treating diseases targeting MABA1
US20060035239A1 (en) Method and compositions for treating diseases targeting CD51

Legal Events

Date Code Title Description
FZDC Discontinued application reinstated
FZDC Discontinued application reinstated

Effective date: 20121228

EEER Examination request

Effective date: 20131104